With a recognized international reputation as a healthcare company and 2,800 employees in 19 countries in Europe, America and Asia., the Zambon group is a pharmaceutical and fine chemicals family enterprise on the market for over 110 years. Respiratory, pain and woman care are the three therapeutic areas of excellence in addition to orphan drugs such as cystic fibrosis, and Parkinson's Disease with the recent launch of a new chemical entity, the first on the market in a decade. Zambon products are marketed in 84 countries and in 2016 revenues amounted to 600 million euros.
In 2016 the different therapeutic areas have achieved the following results:
In 2016, the Industrial Business Operation reached a total production of 163 million packs, an increase of 8% on the previous year with production facilities in Italy, Switzerland, France, Brazil, China. In the past three years, the company has embraced the Industry 4.0 approach, the new frontier of manufacturing production characterized by fully automated and interconnected industrial processes, investing over 10 million euros for the adoption of new technological platforms in Italy and abroad.
Today Zambon is an increasingly global reality in 84 countries of the 5 continents.
The Industrial Business overview: